Cáncer de páncreas: segunda línea, ¿tenemos ahora una opción real de secuenciación?

14 / 24

Randomized Phase 3 trial: MM-398 + 5-
FU/LV as 2nd-line therapy for MPC
(NAPOLI-1)
MM-398
(120 mg/m2 Q3W)
n=151
MM-398 +
5-FU/LV
(80 mg/m2 + 2400 mg/m2 over 46 h /
400 mg/m2 Q2W)
n=117
1:1:1
5-FU/LV
(2000 mg/m 2 over 24 h / 200 mg/m2
weekly Q6W)
n=149
• MPC
• Received prior
gemcitabine-based
therapy
• N=417
R
Primary endpoint: OS
Secondary endpoints: PFS, ORR, CA19-9 response, safety
Stratification: Albumin, KPS, ethnicity
Wang-Gillam et al. Lancet 2015. doi: 10.1016/S0140-6736(15)00986-1
Primary objective OS